Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TOLBUTAMIDE TAB 500MG 500 MG — DIN 00156663

TOLBUTAMIDE : 500 MG · PRO DOC LIMITEE · TABLET · wholesale supply in Canada

Health Canada status: CANCELLED POST MARKET

What is TOLBUTAMIDE TAB 500MG?

TOLBUTAMIDE TAB 500MG 500 MG contains TOLBUTAMIDE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 00156663, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 13-Jul-2010. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.

What is TOLBUTAMIDE TAB 500MG used for?

To control hyperglycemia in tolbutamide responsive diabetes mellitus of stable, mild, nonketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Is there a generic Tolbutamide in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

6 holders have a Canadian DIN containing Tolbutamide, across 7 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
HOECHST CANADA INC.20ORINASE 0.5GM, ORINASE 1GMNo marketed DIN
AA PHARMA INC10TOLBUTAMIDENo marketed DIN
CARTER-HORNER CORP.10MOBENOL TABLETS 500MGNo marketed DIN
DUCHESNAY INC10TOLBUTAMIDE TAB 500MGNo marketed DIN
NOVOPHARM LIMITED10NOVO-BUTAMIDE 500MGNo marketed DIN
PRO DOC LIMITEE10TOLBUTAMIDE TAB 500MGNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label500 MG
Dosage formTABLET
RouteORAL
Pack configuration (monograph)bottles of 100 and 1000
StorageStore at room temperature (15 to 30°C) in a tightly closed container.

Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.

Substance and classification

Active substanceTolbutamide
ATC codeA10BB03
AHFS class68:20.20
Biosimilar biologicNo

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)00156663
DIN (unpadded, as printed on some documents)156663
Brand nameTOLBUTAMIDE TAB 500MG
Generic / active ingredientTOLBUTAMIDE : 500 MG
Market authorization holderPRO DOC LIMITEE
Health Canada schedulePrescription
ATC codeA10BB03
ATC anatomical main groupA — Alimentary tract and metabolism
ATC therapeutic subgroupA10BB
Current statusCANCELLED POST MARKET
Status date13-Jul-2010
Original market date1962-12-31 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

0 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
MOBENOL TABLETS 500MG500 MGTABLETCARTER-HORNER CORP.CANCELLED POST MARKET00013889
NOVO-BUTAMIDE 500MG500 MGTABLETNOVOPHARM LIMITEDCANCELLED POST MARKET00021849
ORINASE 0.5GM500 MGTABLETHOECHST CANADA INC.CANCELLED POST MARKET00012602
ORINASE 1GM1 GTABLETHOECHST CANADA INC.CANCELLED POST MARKET00012610
TOLBUTAMIDE500 MGTABLETAA PHARMA INCDORMANT00312762
TOLBUTAMIDE TAB 500MG500 MGTABLETDUCHESNAY INCCANCELLED POST MARKET00431168

2 · Same class — other molecules in ATC A10BB

MoleculeCanadian brandsDINsMarketedSourceable
GliclazideAG-GLICLAZIDE MR · APO-GLICLAZIDE · APO-GLICLAZIDE MR · AVA-GLICLAZIDE · +17 more3016Yes
GlibenclamideAPO GLYBURIDE TAB 2.5MG · APO GLYBURIDE TAB 5MG · AVA-GLYBURIDE · DIABETA · +24 more444Yes
GlimepirideAMARYL · APO-GLIMEPIRIDE · CO GLIMEPIRIDE · NOVO-GLIMEPIRIDE · +3 more223Yes
ChlorpropamideAPO CHLORPROPAMIDE TAB 100MG · APO CHLORPROPAMIDE TAB 250MG · CHLORPROPAMIDE 100 TAB USP · CHLORPROPAMIDE TAB 250MG · +3 more80Not in Canada
TolbutamideMOBENOL TABLETS 500MG · NOVO-BUTAMIDE 500MG · ORINASE 0.5GM · ORINASE 1GM · +2 more70Not in Canada
AcetohexamideDIMELOR TABLET 1843 500MG10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC A10B

ATC subgroupMoleculesDINsMarketed
A10BDCombinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more12367
A10BHAlogliptin · Linagliptin · Saxagliptin · Sitagliptin9163
A10BAMetformin12245
A10BKCanagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin4230
A10BXNateglinide · Repaglinide · Tirzepatide5430
A10BGPioglitazone · Rosiglitazone9815
A10BJAlbiglutide · Dulaglutide · Exenatide · Liraglutide · Lixisenatide · +1 more3413
A10BFAcarbose62

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 00156663. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.